GLP1R and diabetes mellitus: In this narrative review, we summarize the published literature about the management of diabetes in renal transplants and the use of new agents, namely glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter type 2 inhibitors (SGLT2i), in the kidney transplant field.